-
Safety, tolerability, and concordance with interferon-gamma release assays of a recombinant ESAT6-MPT64 skin test: a phase 1 randomized clinical trial
CONCLUSION: The recombinant EM skin test is safe, well-tolerated, and demonstrates preliminary diagnostic accuracy comparable to IGRAs. By successfully validating the translational utility of the MPT64 (RD2) antigen in a human cohort, this study provides a strong proof-of-concept for the EM skin test as a scalable, specific, and cost-effective immunodiagnostic tool. →
-
Correction: Safety, tolerability, and concordance with interferon-gamma release assays of a recombinant ESAT6-MPT64 skin test: a phase 1 randomized clinical trial
[This corrects the article DOI: 10.3389/fimmu.2026.1780294.]. →
-
Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer
CONCLUSIONS: Morning ICI infusions confer a modest but clinically meaningful survival benefit that is absent in chemotherapy controls, supporting a causal chronotherapeutic effect. Scheduling ICIs before noon represents a low-cost, immediately actionable strategy warranting prospective confirmation. →
-
Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial
BACKGROUND: Nacubactam (OP0595) is a newly developed diazabicyclooctane β-lactamase inhibitor used in combination with cefepime or aztreonam. We assessed the efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam versus imipenem-cilastatin in complicated urinary tract infection (cUTI) or acute uncomplicated pyelonephritis. →
-
The specialisation trap: Why your best hire might not look like one
When the candidate in front of you lacks the specific industry experience you need, the default option is not hire them and move onto the next. However, Oliver, Jiayi, Yasaman, Marisa, Paolo, and Muhammad, argue that the managers who build the strongest teams are those willing to look beyond industry labels, and instead assess a… →
-
How Job Design for Disability Improves Work for Everyone
Gary Waters / Ikon Images Disability-related innovations are all around us. Curb cuts in sidewalks, originally designed for wheelchair users, benefit caregivers with strollers, travelers with suitcases, and delivery workers with hand trucks. Automatic doors intended for individuals with mobility impairments are convenient for all. Blurred backgrounds in video calls, standing desks and ergonomic keyboards,… →
-
What Have We Learned From the Idiopathic Intracranial Hypertension Treatment Trial the William F. Hoyt Lecture
CONCLUSIONS: Acetazolamide plus diet gave statistically significant improvements of visual function, papilledema, CSF pressure, and quality of life in patients with IIH with mild visual loss. A maximally tolerated dose up to 4 g/day is recommended. →
-
Mode Effects Between Mobile Web and Telephone Surveys on Patient Experience Scores in South Korea: Secondary Analysis of a Randomized Controlled Trial Under Various Missingness Scenarios
CONCLUSIONS: Mobile surveys may yield substantially lower patient experience scores than telephone surveys. Unlike previous studies, our study analyzes randomized experimental data under various missingness scenarios and provides evidence that this mode effect is unlikely to be attributable to analytical methods or heterogeneity in respondent characteristics between the 2 survey administration modes. Accordingly, caution is… →
-
Treatment of Clinically Diagnosed Alzheimer’s Disease by External Counterpulsation A Randomized Clinical Trial
ObjectiveTo assess external counterpulsation (ECP) effects on cognitive and functional decline in early AD.MethodsThis 12-month, multicenter, blinded, randomized, sham-controlled trial enrolled 190 patients with early AD (MCI due to AD or mild AD per NIA-AA clinical criteria). Participants received either full-pressure ECP (150-300 mmHg) or sham (25 mmHg): 3-5 weekly one-hour sessions for 35 treatments,… →
-
Inside Reevo’s $80M Bet to Kill the $10B Frankenstein Stack | David Zhu, Cofounder & CEO
The GTM Podcast is available on any major directory, including: Apple Podcasts Spotify YouTube AI is rewriting go-to-market and most companies are still operating with a “Frankenstein stack.” In this episode of GTMnow, we sit down with David Zhu, founder & CEO of Reeva, to unpack how AI-native companies will replace legacy GTM systems, why the… →